Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Switching of integrase inhibitors (dolutegravir, raltegravir and elvitegravir) due to adverse events to other antiretroviral treatments in patients with HIV infection: A three retrospective study

Trial Profile

Switching of integrase inhibitors (dolutegravir, raltegravir and elvitegravir) due to adverse events to other antiretroviral treatments in patients with HIV infection: A three retrospective study

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Dolutegravir (Primary) ; Elvitegravir (Primary) ; Raltegravir (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Aug 2017 New trial record
    • 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top